MiniMed Expands European Sensor Options with Abbott's Instinct CGM
Event summary
- MiniMed receives CE Mark approval for MiniMed™ 780G system with Abbott's Instinct sensor in Europe.
- Instinct sensor offers up to 15 days of wear, the longest duration among MiniMed-compatible sensors.
- MiniMed™ 780G system now compatible with three sensors: Guardian™ 4, Simplera Sync™, and Instinct.
- Commercial launch expected in select European countries during summer 2026.
- MiniMed Go™ Smart MDI system with Instinct Go sensor also receives CE Mark approval.
The big picture
MiniMed's strategic move to expand sensor choices for its automated insulin delivery system aligns with the broader industry trend towards personalized diabetes management. By integrating Abbott's Instinct sensor, MiniMed enhances its competitive edge in Europe, where the system is already approved for a wider age range and use cases compared to the U.S. This expansion could potentially drive higher adoption rates and strengthen MiniMed's position as a leader in full-stack insulin delivery solutions.
What we're watching
- Market Penetration
- How MiniMed's expanded sensor options will affect its market share in Europe.
- Regulatory Dynamics
- Whether the CE Mark approval will accelerate MiniMed's approval process in other regions.
- Competitive Positioning
- The pace at which competitors like Dexcom and Medtronic respond with similar sensor integrations.